The role of resveratrol in inhibiting the development and progression of oxidative stress-induced retinal diseases Review article

Main Article Content

Małgorzata Figurska

Abstract

In recent years, the importance of resveratrol as a biologically active natural nutrient with potential to prevent the development and progression of age-related degenerative diseases has been analyzed. The aim of the study is to review the current literature from the last 10 years or so, dealing with the subject of resveratrol properties, its impact on systemic condition and retinal diseases. This review confirms the important beneficial role of resveratrol and dietary supplements containing resveratrol in limiting the development and progression of diseases related to oxidative stress. The range of action of resveratrol is systemic, as evidenced by research. In ophthalmology, resveratrol is used primarily in degenerative retinal diseases and complications of metabolic diseases in which oxidative stress plays a key role. The data from the conducted studies provide the basis for the assumption that thanks to compounds such as resveratrol, we may gain a real impact on the occurrence of e.g. age-related macular degeneration and its course.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Figurska M. The role of resveratrol in inhibiting the development and progression of oxidative stress-induced retinal diseases . Ophthatherapy [Internet]. 2024Mar.31 [cited 2024Oct.3];11(1):30-5. Available from: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/2980
Section
Conservative treatment

References

1. Pop R, Daescu A, Rugina D et al. Resveratrol: its path from isolation to therapeutic action in eye diseases. Antioxidants. 2022; 11(12): 2447.
2. Nashine S, Nesburn AB, Kuppermann BD et al. Role of resveratrol in transmitochondrial AMD RPE cells. Nutrients. 2020; 12(1): 159.
3. Bhattarai N, Korhonen E, Toppila M et al. Resvega alleviates hydroquinone-induced oxidative stress in ARPE-19 cells. Int J Mol Sci. 2020; 21(6): 2066. http://doi.org/10.3390/ijms21062066.
4. Zhou DD, Luo M, Huang SY et al. Effects and Mechanisms of Resveratrol on Aging and Age-Related Diseases. Oxid Med Cell Longev. 2021; 2021: 9932218. http://doi.org/10.1155/2021/9932218.
5. Kou X, Chen N. Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer’s Disease. Nutrients. 2017; 9(9): 927. http://doi.org/10.3390/nu9090927.
6. Zhao YN, Li WF, Li F et al. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem Biophys Res Commun. 2013; 435(4): 597-602. http://doi.org/10.1016/j.bbrc.2013.05.025.
7. Bonnefont-Rousselot D. Resveratrol and Cardiovascular Diseases. Nutrient. 2016; 8(5): 250. http://doi.org/10.3390/nu8050250.
8. Le Clanche S, Cheminel T, Rannou F et al. Use of Resveratrol Self-Emulsifying Systems in T/C28a2 Cell Line as Beneficial Effectors in Cellular Uptake and Protection Against Oxidative Stress-Mediated Death Front. Pharmacol. 2018; 9: 538. http://doi.org/10.3389/fphar.2018.00538.
9. Brown RB. Phospholipid packing defects and oxysterols in atherosclerosis: Dietary prevention and the French paradox Biochimie. 2019; 167: 145-51. http://doi.org/10.1016/j.biochi.2019.09.020.
10. Fleckenstein M, Keenan TDL, Guymer RH et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021; 7(1): 31. http://doi.org/10.1038/s41572-021-00265-2.
11. Arunkumar R, Bernstein PS. Macular Pigment Carotenoids and Bisretinoid A2E. Adv Exp Med Biol. 2023; 1415: 15-20. http://doi.org/10.1007/978-3-031-27681-1.
12. Crouch RK, Koutalos Y, Kono M et al. A2E and Lipofuscin. Prog Mol Biol Transl Sci. 2015; 134: 449-63. http://doi.org/10.1016/bs.pmbts.2015.06.005.
13. Agron E, Mares J, Clemons TE et al. Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2. Ophthalmology. 2021; 128(3): 425-42.
14. Van Leeuwe EM, Emri E, Merle BMJ et al. A new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res. 2018; 67: 56-86.
15. Merle BM, Silver RE, Rosner B et al. Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: a prospective cohort study. Am J Clin Nutr. 2015; 102(5): 1196-206. http://doi.org/10.3945/ajcn.115.111047.
16. Chew EY. Nutrition effects on ocular diseases in the aging eye. Invest Ophthalmol Vis Sci. 2013; 54(14): ORSF42-7. http://doi.org/10.1167/iovs13-12914.
17. Mauschitz MM, Finger RP. Age-Related Macular Degeneration and Cardiovascular Diseases: Revisiting the Common Soil Theory. Asia Pac J Ophthalmol (Phila). 2022; 11(2): 94-9. http://doi.org/10.1097/APO.0000000000000496.
18. Alaimo A, Di Santo MC, Domínguez Rubio AP et al. Toxic effects of A2E in human ARPE-19 cells were prevented by resveratrol: a potential nutritional bioactive for age-related macular degeneration treatment. Arch Toxicol. 2020; 94(2): 553 72. http://doi.org/10.1007/s00204-019-02637-w.
19. Kang JH, Choung SY. Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro. Arch Pharm Res. 2016; 39(12): 1703-15. http://doi.org/10.1007/s12272-016-0839-0.
20. Lee BL, Kang JH, Kim HM et al. Polyphenol-enriched Vaccinium uliginosum L. fractions reduce retinal damage induced by blue light in A2E-laden ARPE19 cell cultures and mice. Nutr Res. 2016; 36(12): 1402-14. http://doi.org/10.1016/j.nutres.2016.11.008.
21. Courtaut F, Aires V, Acar N et al. RESVEGA, a nutraceutical omega-3/resveratrol supplementation, reduces angiogenesis in a preclinical mouse model of choroidal neovascularization. Int J Mol Sci. 2021; 22(20): 11023.
22. Bhattarai N, Korhonen E, Toppila M et al. Resvega alleviates hydroquinone-induced oxidative stress in ARPE-19 cells. Int J Mol Sci. 2020; 21(6): 2066. http://doi.org/10.3390/ijms21062066.
23. Koskela A, Reinisalo M, Petrovski G et al. Nutraceutical with resveratrol and omega-3 fatty acids induces autophagy in ARPE-19 cells. Nutrients. 2016; 8(5): 284. http://doi.org/10.3390/nu8050284.
24. Berman AY, Motechin RA, Wiesenfeld MY et al. The therapeutic potential of resveratrol: a review of clinical trials. Npj Precis Oncol. 2017; 1: 35. http://doi.org/10.1038/s41698-017-0038-6.
25. Richer S, Stiles W, Ulanski L et al. Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement. Nutrients. 2013; 5(6): 1989-2005.
26. Richer S, Patel S, Sockanathan S et al. Resveratrol based oral nutritional supplement produces long-term beneficial effects on structure and visual function in human patients. Nutrients. 2014; 6(10): 4404-20.
27. Datseris I, Bouratzis N, Kotronis C et al. One-year outcomes of resveratrol supplement with aflibercept versus aflibercept monotherapy in wet age-related macular degeneration. Int J Ophthalmol. 2023; 16(9): 1496-1502. http://doi.org/10.18240/ijo.2023.09.17.
28. Casten RJ, Rovner BW. Update on depression and age-related macular degeneration. Curr Opin Ophthalmol. 2013; 24(3): 239-43.
29. Senra H, Ali Z, Balaskas K et al. Psychological impact of anti-VEGF treatments for wet macular degeneration – a review. Graefes Arch Clin Exp Ophthalmol. 2016; 254(10): 1873-80.
30. Moore A, Beidler J, Hong MY. Resveratrol and depression in animal models: a systematic review of the biological mechanisms. Molecules. 2018; 23(9): 2197. http://doi.org/10.3390/molecules23092197.
31. Ge JF, Xu YY, Qin G et al. Resveratrol ameliorates the anxiety- and depression-like behavior of subclinical hypothyroidism rat: possible involvement of the HPT axis, HPA axis, and Wnt/β-catenin pathway. Front Endocrinol (Lausanne). 2016; 7: 44. http://doi.org/10.3389/fendo.2016.00044.
32. Zhang J, Zhang J, Zhang C et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022; 11(21): 3362. http://doi.org/10.3390/cells11213362.
33. Chatziralli I, Dimitriou E, Chatzirallis A et al. Efficacy and safety of vitamin supplements with resveratrol in diabetic macular edema: Long-term results of a comparative study. Eur J Ophthalmol. 2022; 32(5): 2735-9. http://doi.org/10.1177/11206721211057682.